- Protools 12 instrument bundle pro#
- Protools 12 instrument bundle software#
- Protools 12 instrument bundle plus#
- Protools 12 instrument bundle professional#
Protools 12 instrument bundle pro#
Perfect setup for your needs with a wide array of Pro Tools solutions-from PC-using Pro Tools, the industry-standard audio production platform.
Protools 12 instrument bundle software#
Pro Tools software 10 is the new generation of sound editing software commercially available.Ĭompose, record, edit, and mix high-quality music or sound for picture-on a Mac or Whether you are designing music or sound, the right tools can help you achieve the highest quality and faster mix. In addition, you can use Pro Tools software 10 along with other new features and workflow. This software comes with Pro Tools | HDX and Pro Tools | HD.
Protools 12 instrument bundle professional#
This powerful software will help you with your professional setup, recording, editing and mixing of the greatest music productions. All rights reserved.Avid Pro Tools HD 12 is a software for recording, editing and mixing audio files and one of the most professional audio platforms in the world. Further clinical trials are needed to establish the best treatment duration and to further assess the contribution of ribavirin.Ĭ NCT01726517 NCT01329978 NCT01726517.Ĭopyright © 2014 Elsevier Ltd. These findings suggest that the fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to cure most patients with genotype-1 HCV, irrespective of treatment history or the presence of compensated cirrhosis. One patient in group five had a serious adverse event of anaemia, thought to be related to ribavirin treatment. The most common adverse events were nausea, anaemia, upper respiratory tract infection, and headache. Two patients had viral relapse one patient was lost to follow-up after achieving sustained virological response 8 weeks after treatment. In cohort B, SVR12 was achieved by 18 (95%) of 19 patients (74-100) in group 4 and by all 21 (100%) of 21 patients (84-100) in group 5. This study is registered with, number NCT01329978. The primary endpoint was sustained virological response 12 weeks after treatment (SVR12), analysed by intention to treat. 22 (55%) of 40 patients in cohort B had compensated cirrhosis.
Protools 12 instrument bundle plus#
In cohort B, we randomly allocated (1:1 stratified by genotype and presence or absence of cirrhosis) 40 patients who previously had virological failure after receiving a protease inhibitor regimen to receive sofosbuvir plus ledipasvir for 12 weeks (group 4) or sofosbuvir plus ledipasvir and ribavirin for 12 weeks (group 5). In cohort A, we used a computer-generated sequence to randomly assign (1:1:1 stratified by HCV genotype ) 60 non-cirrhotic, treatment-naive patients to receive sofosbuvir plus ledipasvir for 8 weeks (group 1), sofosbuvir plus ledipasvir and ribavirin for 8 weeks (group 2), or sofosbuvir plus ledipasvir for 12 weeks (group 3). We assessed the efficacy and safety of an interferon-free regimen-a fixed-dose combination of the nucleotide polymerase inhibitor sofosbuvir (400 mg) and the HCV NS5A inhibitor ledipasvir (90 mg), with and without ribavirin-in patients with genotype-1 hepatitis C infection who were treatment-naive or previously treated with a protease-inhibitor regimen.įor this open-label study, we enrolled 100 adult patients (>18 years) with HCV infection at a centre in the USA between Nov 2, 2012, and Dec 21, 2012. Interferon-based treatment is not suitable for many patients with hepatitis C virus (HCV) infection because of contraindications such as psychiatric illness, and a high burden of adverse events.
0 kommentar(er)
